Citation Impact
Citing Papers
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
2013 Standout
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
2007
Regional anesthesia in the anticoagulated patient: Defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation)
2003
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Nonlinear magic: multiphoton microscopy in the biosciences
2003 Standout
Mechanisms of Thrombus Formation
2008 Standout
The third dimension bridges the gap between cell culture and live tissue
2007 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis
2008 Standout
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
2004
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
2010 Standout
Antithrombotic Therapy for VTE Disease
2016 Standout
Risk Factors for Heparin-Induced Thrombocytopenia Type II in Aneurysmal Subarachnoid Hemorrhage
2011
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2008 Standout
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
1996 Standout
Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders
2009
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis
2003
Heparin-Induced Thrombocytopenia
2006 Standout
Long-term effects of weight-reducing diets in hypertensive patients
2011
Prevention of Venous Thromboembolism
2004 Standout
Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering
2005 Standout
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
1999 Standout
β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease
2012
Pre-eclampsia
2010 Standout
Long-term effects of weight-reducing drugs in hypertensive patients
2013
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
2010 Standout
Prevention of Venous Thromboembolism
2008 Standout
Antithrombotic Therapy in Neonates and Children
2008
Antithrombotic Therapy in Neonates and Children
2012
Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis
2001
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Long-term Treatment of Deep Venous Thrombosis with a Low Molecular Weight Heparin (Tinzaparin): A Prospective Randomized Trial
2005
Antithrombotic Therapy During Percutaneous Coronary Intervention
2004
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis
1992
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight Heparins
1990
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial
2015
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness
2010 Standout
Low molecular weight heparin in prevention of perioperative thrombosis.
1992
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2018
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
2013 Standout
Compensation mechanism in tumor cell migration
2003
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Serpin Structure, Mechanism, and Function
2002 Standout
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
2010 Standout
Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
2005
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
2006 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty
2020
Diagnosis and Management of Cerebral Venous Thrombosis
2011 Standout
Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia
2006
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage
2012 Standout
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
2021 Standout
Low-Molecular-Weight Heparins
1997 Standout
Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal
2014 Standout
Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin
1994
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
2021 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin
2008
2020 International Society of Hypertension Global Hypertension Practice Guidelines
2020 Standout
Regional Anesthesia in the Anticoagulated Patient
2003
Works of Peter Bacher being referenced
Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin
1994
Verapamil-sustained release–based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INternational VErapamil SR-Trandolapril (INVEST) substudy
2008
Evaluation of Hemostatic and Fibrinolytic Alterations Associated with Daily Administration of Low-Molecular-Weight Heparin for a 12-Week Period
1995
Risk factor assessment for new onset diabetes: literature review
2008
The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model
1992
Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies
2002
Decreased Prevalence of Heparin-Induced Thrombocytopenia with Low-Molecular-Weight Heparin and Related Drugs
2004
Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin–sodium) in pediatric patients
2003
Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial
2008
A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty.
2001
Prevention of deep vein thrombosis in orthopedic surgery: Fragmin versus Heparin-DHE
1987
Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome
2006
Drug-Induced Alterations of Hemostasis and Fibrinolysis
1992